Short summary

A prospective pilot study on 16 patients suffering from peritoneal metastasis originating from: gastric, pancreatic, ovarian, and colorectal cancer. Patients are treated in a series of three PIPACs; peritoneal biopsies are taken during each treatment and evaluated according to PRGS. The FDG-PET/CT scans will be completed at baseline and after PIPAC 1 and 3. The primary objective is the number of patients with metabolic response according to FDG-PET/CT evaluated by PERCIST 1.0 after PIPAC 3.

Rationale

Peritoneal metastasis (PM) is a late-stage manifestation of several gastro-intestinal cancers. These patients often present with severe symptoms such as pain, ascites, and gastrointestinal obstruction, which deteriorate their activities of daily living and quality of life. if left untreated most patients will die form their disease within three to six months. A novel treatment strategy, Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) has demonstrated significant local treatment effect and promising survival. The technical aspects of PIPAC are nearly uniform worldwide, but there is no consensus on the optimal evaluation of treatment response. FDG-PET/CT shows promising results concerning visualization and assessing PM lesions, but no studies have investigated the ability of these scans to detect changes in PM during PIPAC treatment. Therefore, we want to conduct a prospective study to investigate if FDG-PET/CT scans can detect changes within PM lesions in patients treated with PIPAC directed therapy. Since the study is the first of its kind, we will start with a pilot study.

Description of the cohort

The study cohort will consist of patients with PM originating form either gastric, pancreatic, ovarian or colorectal cancer eligebel for PIPAC directed therapy.

Data and biological material

Demographic data, information about primary diagnosis and PM diagnosis, information about the PIPAC procedures, patological descriptions according to PRGS, FDG-PET/CT scan descriptions according to PERCIST 1.0.

Collaborating researchers and departments

Department of Nuclear Medicine, Odense University Hospital

• Malene Grubbe Hildebrandt

Department of Clinical Pathology, Odense University Hospital

• Sönke Detlefsen

Department of Clinical Oncology, Odense University Hospital

• Per Pfeiffer

Department of Surgery, Odense University Hospital

• Michale Bau Mortensen